The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
Cd. Autonoma de Buenos Aires, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Corrientes, Argentina